JP2023500360A - Ｎ－アセチルシステインの鼻腔内投与のための用量、製剤、およびデバイスを較正および選択するための磁気共鳴分光法の使用 - Google Patents

Ｎ－アセチルシステインの鼻腔内投与のための用量、製剤、およびデバイスを較正および選択するための磁気共鳴分光法の使用 Download PDF

Info

Publication number
JP2023500360A
JP2023500360A JP2022526378A JP2022526378A JP2023500360A JP 2023500360 A JP2023500360 A JP 2023500360A JP 2022526378 A JP2022526378 A JP 2022526378A JP 2022526378 A JP2022526378 A JP 2022526378A JP 2023500360 A JP2023500360 A JP 2023500360A
Authority
JP
Japan
Prior art keywords
nac
brain
gsh
administration
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022526378A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500360A5 (https=
Inventor
ダグラス エー． グリーン，
Original Assignee
ニューロネイザル， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューロネイザル， インコーポレイテッド filed Critical ニューロネイザル， インコーポレイテッド
Publication of JP2023500360A publication Critical patent/JP2023500360A/ja
Publication of JP2023500360A5 publication Critical patent/JP2023500360A5/ja
Priority to JP2025076413A priority Critical patent/JP2025107344A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
    • G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/46—NMR spectroscopy
    • G01R33/465—NMR spectroscopy applied to biological material, e.g. in vitro testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/483—NMR imaging systems with selection of signals or spectra from particular regions of the volume, e.g. in vivo spectroscopy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
JP2022526378A 2019-11-04 2020-11-04 Ｎ－アセチルシステインの鼻腔内投与のための用量、製剤、およびデバイスを較正および選択するための磁気共鳴分光法の使用 Pending JP2023500360A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025076413A JP2025107344A (ja) 2019-11-04 2025-05-01 Ｎ－アセチルシステインの鼻腔内投与のための用量、製剤、およびデバイスを較正および選択するための磁気共鳴分光法の使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962930473P 2019-11-04 2019-11-04
US62/930,473 2019-11-04
PCT/US2020/058905 WO2021092026A1 (en) 2019-11-04 2020-11-04 Use of magnetic resonance spectroscopy to calibrate and select doses, formulations, and devices for intra-nasal administration of n-acetylcysteine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025076413A Division JP2025107344A (ja) 2019-11-04 2025-05-01 Ｎ－アセチルシステインの鼻腔内投与のための用量、製剤、およびデバイスを較正および選択するための磁気共鳴分光法の使用

Publications (2)

Publication Number Publication Date
JP2023500360A true JP2023500360A (ja) 2023-01-05
JP2023500360A5 JP2023500360A5 (https=) 2023-11-28

Family

ID=75688247

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022526378A Pending JP2023500360A (ja) 2019-11-04 2020-11-04 Ｎ－アセチルシステインの鼻腔内投与のための用量、製剤、およびデバイスを較正および選択するための磁気共鳴分光法の使用
JP2025076413A Pending JP2025107344A (ja) 2019-11-04 2025-05-01 Ｎ－アセチルシステインの鼻腔内投与のための用量、製剤、およびデバイスを較正および選択するための磁気共鳴分光法の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025076413A Pending JP2025107344A (ja) 2019-11-04 2025-05-01 Ｎ－アセチルシステインの鼻腔内投与のための用量、製剤、およびデバイスを較正および選択するための磁気共鳴分光法の使用

Country Status (7)

Country Link
US (2) US20210128509A1 (https=)
EP (1) EP4054410A4 (https=)
JP (2) JP2023500360A (https=)
CN (1) CN115515484A (https=)
AU (1) AU2020380291A1 (https=)
CA (1) CA3160283A1 (https=)
WO (1) WO2021092026A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3618824A4 (en) * 2017-05-02 2021-06-23 Neuronasal, LLC USE OF N-ACETYLCYSTONE FOR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
US12594254B2 (en) * 2022-02-07 2026-04-07 Neuronasal, Inc. Intranasal administration of n-acetylcysteine and uses thereof
WO2023192691A2 (en) * 2022-04-01 2023-10-05 Wake Forest University Health Sciences Methods and formulations for intranasal delivery of insulin in the treatment of diabetic eye disease
US20250371713A1 (en) * 2024-05-28 2025-12-04 Debra Strick Rivera Mapping glutathione deficiency and/or dysfunction of mitochondria

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010507572A (ja) * 2006-10-23 2010-03-11 ザ メンタル ヘルス リサーチ インスティチュート オブ ビクトリア 併用療法
WO2018204393A1 (en) * 2017-05-02 2018-11-08 Neuronasal, Llc Use of n-acetylcysteine to treat central nervous system disorders
WO2019084543A1 (en) * 2017-10-27 2019-05-02 Beyond Barriers Therapeutics, Inc. ENHANCED ANTIOXIDANT ADMINISTRATION FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS INVOLVING OXIDATIVE STRESS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2871774C (en) * 2012-04-26 2021-05-18 Sentient Lifesciences, Inc. Use of n-acetylcysteine amide in the treatment of disease and injury
ES2844199T3 (es) * 2013-04-16 2021-07-21 Childrens Hospital Philadelphia Composiciones y métodos para el tratamiento de lesiones cerebrales
CA3165422A1 (en) * 2019-12-18 2021-06-24 Neuronasal, Inc. Methods of treating brain disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010507572A (ja) * 2006-10-23 2010-03-11 ザ メンタル ヘルス リサーチ インスティチュート オブ ビクトリア 併用療法
WO2018204393A1 (en) * 2017-05-02 2018-11-08 Neuronasal, Llc Use of n-acetylcysteine to treat central nervous system disorders
WO2019084543A1 (en) * 2017-10-27 2019-05-02 Beyond Barriers Therapeutics, Inc. ENHANCED ANTIOXIDANT ADMINISTRATION FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS INVOLVING OXIDATIVE STRESS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, vol. 38:2, JPN6024044184, January 2019 (2019-01-01), pages 1 - 15, ISSN: 0005451040 *

Also Published As

Publication number Publication date
CN115515484A (zh) 2022-12-23
EP4054410A4 (en) 2024-07-17
US20210128509A1 (en) 2021-05-06
WO2021092026A1 (en) 2021-05-14
CA3160283A1 (en) 2021-05-14
AU2020380291A1 (en) 2022-05-26
EP4054410A1 (en) 2022-09-14
JP2025107344A (ja) 2025-07-17
US20230321020A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
AU2022283769B2 (en) Neuroactive steroids, compositions, and uses thereof
US20230321020A1 (en) Magnetic resonance spectroscopy to calibrate and select doses, formulations, and devices for intra-nasal administration of n-acetylcysteine
US12414929B2 (en) Methods of treating brain disorders
TWI326214B (en) Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
US20220152055A1 (en) Methods and compositions for treating various disorders
US9018170B2 (en) Reduced volume formulation of glatiramer acetate and methods of administration
US20240082225A1 (en) Methods for the treatment of dyskinesia in cerebral palsy
CN113825510A (zh) 使用氘化右美沙芬和奎尼丁治疗精神分裂症的阴性症状的方法
US20240024267A1 (en) Methods of administering glutathione precursors
US20200038420A1 (en) Aminosterol compositions and methods of using the same for treating depression
Bîrluţiu et al. Facial palsy at the onset of SARS-CoV-2 infection. A case report
Akgun et al. Central nervous system stimulants and drugs that suppress appetite
CN121175045A (zh) 用于治疗夏科-马里-图思病的组合物和方法
WO2023099013A1 (en) Methods of treating patients suffering from brain injury and methods of increasing the value of the extended glasgow outcome scale of patients suffering from brain injury
HK40060751A (en) Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine
HK1152249B (en) Reduced volume formulation of glatiramer acetate and methods of administration

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260423